Skip to main content
BTC / USDT107,400+2.19%ETH / USDT3,840+2.13%SOL / USDT182.40−1.99%BNB / USDT652.30+0.66%XRP / USDT2.2150+1.61%DOGE / USDT0.3850−1.79%TON / USDT5.240+2.34%AVAX / USDT42.60−2.07%LINK / USDT22.40+2.28%ADA / USDT1.0520−1.68%TRX / USDT0.3300+0.92%DOT / USDT8.420+2.93%BTC / USDT107,400+2.19%ETH / USDT3,840+2.13%SOL / USDT182.40−1.99%BNB / USDT652.30+0.66%XRP / USDT2.2150+1.61%DOGE / USDT0.3850−1.79%TON / USDT5.240+2.34%AVAX / USDT42.60−2.07%LINK / USDT22.40+2.28%ADA / USDT1.0520−1.68%TRX / USDT0.3300+0.92%DOT / USDT8.420+2.93%
AboutTraders FairTraders AwardsTrade Game
/
Pricing
Get started→
stocksJul 16, 2026, 10:45 AM

Lilly to Acquire Atai Life Sciences for $2.8B Upfront Plus CVR

Eli Lilly will acquire Atai Life Sciences for $6.75 per share in cash plus up to $2.50 per share in contingent value rights, valuing the deal at $2.8 billion upfront with potential additional $1 billion. The transaction is expected to close in the third quarter, subject to regulatory approvals.

LLYATAI

Eli Lilly (LLY) announced it will acquire Atai Life Sciences (ATAI) in a deal valued at $2.8 billion upfront, with up to $1 billion in contingent value rights (CVRs).

Under the terms, Atai shareholders will receive $6.75 per share in cash plus up to $2.50 per share in CVRs. The acquisition is intended to advance therapies for treatment-resistant depression and other mental health conditions.

The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions and regulatory approvals.

Source: First Squawk